Skip to main content
main-content

15.06.2017 | Original Paper | Ausgabe 3/2018

International Ophthalmology 3/2018

Treatment of patients with neurotrophic keratitis stages 2 and 3 with plasma rich in growth factors (PRGF-Endoret) eye-drops

Zeitschrift:
International Ophthalmology > Ausgabe 3/2018
Autoren:
Ronald Mauricio Sanchez-Avila, Jesus Merayo-Lloves, Ana Cristina Riestra, Luis Fernandez-Vega Cueto, Eduardo Anitua, Leire Begoña, Francisco Muruzabal, Gorka Orive

Abstract

Purpose

To provide preliminary data about efficacy and safety of plasma rich in growth factors (PRGF) eye-drops in neurotrophic keratitis (NK) and to analyze the possible influence of certain variables on treatment outcomes.

Methods

This retrospective study included patients with stages 2–3 of NK treated with PRGF eye-drops. Primary endpoint was the resolution time of corneal ulcer defect. Outcome measures including percentage of ulcer closure at 4 weeks, Ocular Surface Disease Index (OSDI), Best-Corrected Visual Acuity (BCVA) and Visual Analogue Scale (VAS) were also evaluated before and after treatment with PRGF. The influence of some patients’ clinical variables on results was assessed. Safety assessment was also performed reporting all adverse events.

Results

Thirty-eight treated eyes in a total of thirty-one patients were evaluated, of which five cases had no prior response to autologous serum treatment. Most cases (97.4%) achieved the complete resolution of corneal defect/ulcer. Mean resolution time was 11.4 weeks (SD = 13.7). A statistical significant (p < 0.05) reduction in OSDI (60.9%), VAS frequency (59.9%), VAS severity (57.0%) and improvement in BCVA (52.8%) was observed. The results were stratified according to the pathology stage and to the identified potential effect modifiers variables. Only one adverse event was reported in one patient (2.6%).

Conclusions

PRGF eye-drops could be a safe and effective therapeutic option for patients with stages 2–3 of NK, showing high rates of corneal defect/ulcer resolution in short times, either in reducing signs and symptoms of NK, and therefore preventing the progression of NK to greater ocular complications.

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

★ PREMIUM-INHALT
e.Med Interdisziplinär

Mit e.Med Interdisziplinär erhalten Sie Zugang zu allen CME-Fortbildungen und Premium-Inhalten der Fachzeitschriften, inklusive eines Print-Abos.

Literatur
Über diesen Artikel

Weitere Artikel der Ausgabe 3/2018

International Ophthalmology 3/2018Zur Ausgabe

Neu im Fachgebiet Augenheilkunde

15.06.2018 | Video plus | Ausgabe 7/2018

Diakaustische Kammerwinkeluntersuchung

Videobeitrag

01.06.2018 | themenschwerpunkt | Ausgabe 3/2018

Das Kind in der Kunst

22.05.2018 | Das Frühgeborene | Leitthema | Ausgabe 6/2018

Frühgeborenenretinopathie in welchem Stadium wie behandeln?

Aktueller Wissensstand und Ausblick